HIGHLIGHTS
- who: Jun Hirai and colleagues from the ampicillin/sulbactamampicillin/sulbactamDepartment of Clinical Infectious Diseases, Aichi Medical University Hospital, Nagakute, Japan have published the research work: Comparative Effectiveness of Ampicillin/Sulbactam versus Cefazolin as Targeted Therapy for Bacteremia Caused by Beta-Lactamase-Producing Methicillin-Sensitive Staphylococcus aureus: A Single-Center Retrospective Study, in the Journal: Antibiotics 2022, 11, 1505. of 22/09/2022
- what: The authors aimed to compare the clinical efficacy and adverse effects of SAM CFZ in patients with BP-MSSA bacteremia. This study showed that SAM treatment for BP-MSSA bacteremia had no . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.